检索结果-南通市图书馆

Boceprevir plus peginterferon/ribavirin for treatment ofchronic hepatitis C in Russia

World Journal of Hepatology 2016年第6期8卷 331-339页

作者： Vasily Isakov Igor Nikitin Vladimir Chulanov pavel Ogurtsov Ekaterina Lukyanova Jianmin Long JaniceWahl Frans A Helmond the p08160 trial investigators Department of Gastroenterology and Hepatology Institute of NutritionMoscow 115446Russia Department of Gastroenterology and Hematology Russian Academy of SciencesMoscow 117593Russia Clinical Diagnostics and Research Center Central Research Institute of EpidemiologyMoscow 111123Russia Hospital Medicine Peoples’Friendship University of RussiaMoscow 117198Russia Medical Affairs MSD Pharmaceuticals LLCMoscow 115093Russia Clinical Research Merck&Co.Inc.KenilworthNJ 07033United States 不详

AIM: to evaluate addition of boceprevir to peginterferon/ribavirin(pR) in Russian patients with chronic hepatitis C virus(HCV).METHODS: treatment-naive(t N) and treatmentexperienced(t E) patients(who had failed prior treatment with pR for ≥ 12 wk) with chronic HCV genotype 1 infection were enrolled in this placebocontrolled, double-blind study. All patients initially received pR for 4 wk. patients randomized to control treatment then received pR for an additional 44 wk. t N patients randomized to triple therapy received boceprevir(800 mg three times daily) plus pR for 24 wk and then further therapy according to treatment week 8(t W8) HCV RNA levels. t E patients received boceprevir plus pR for 32 wk and then further therapy according to t W8 HCV RNA levels. treatment was discontinued for t N patients with detectable HCV RNA at t W24 and t E patients with detectable HCV RNA at t W12 because of futility. the primary efficacy end point was sustained virologic response(SVR) defined as undetectable HCV RNA 24 wk after completing all study ***: SVR was 74.8% in the boceprevir plus pR arm compared with 46.2% in the control arm, with a stratification-adjusted treatment difference of 29.2%(95%CI: 16.4-41.5; p previr arm in both t N and t E patient groups(t N 78.4% vs 56.3%; t E 69.4% vs 30.0%). Within t E patients, the rates of SVR were higher with boceprevir plus pR compared with pR, regardless of treatment failure type(null responder, partial responder, and relapser). Most patients receiving boceprevir plus pR in both t N(86%) and t E(71%) populations were eligible for reduced treatment duration. Anemia was increased in patients receiving boceprevir plus pR vs pR alone(47.2% vs 24.4%); there was a corresponding increase in ribavirin dose reduction and erythropoietin use. Among patients receiving boceprevir plus pR, SVR rates were similar in patients with anemia(< 10 g/d L) and those without anemia(71.2% vs 77.4%).C

关键词： hepatitis C virus boceprevir peginterferon ribavirin randomized clinical trial sustained virologicresponse

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Association between stress hyperglycemia ratio and in-hospital outcomes:findings from the improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome(CCC-ACS)project

引用

Journal of Geriatric Cardiology 2024年第6期21卷 658-668页

作者： Wen-Jie WANG Ke-Xin WANG Jia-Long NIU Yi-Xuan LIU Hai-Long GE Hua SHEN On behalf of CCC-ACS investigators Department of Cardiology Beijing Anzhen HospitalCapital Medical UniversityBeijingChina

BACKGROUND Stress hyperglycemia ratio(SHR)could provide accurate information on the acute status of *** relationship between SHR and acute coronary syndrome(ACS)prognosis remains *** study was conducted to identity the association between SHR and in-hospital outcomes in patients with *** A total of 12,010 patients were eventually enrolled in the *** relationship between SHR and in-hospital major adverse cardiovascular events(MACEs)was then modeled by restricted cubic spline(RCS)curves,and all patients were divided into three groups according to the *** multivariate logistic regression analysis was used to determine the associations between the SHR and in-hospital outcomes,described as odds ratios(ORs)and 95%confidence intervals(CIs).Subgroup analyses were also performed on different *** The median age of this cohort was 63(54,71)years old,and 8942(74.5%)were *** 1 was defined as SHRp 2 was defined as SHR between 0.6 and 1(n=5821),and Group 3 was defined as SHR>1(n=5763).Compared with Group 2,Group 1(OR=1.891,95%CI:1.028-3.479,pp 3(OR=1.868,95%CI:1.434-2.434,ppital *** was associated with higher risks of in-hospital MACEs in the subgroups of DM[OR=2.282,95%CI:1.477-3.524).CONCLUSIONS Both low and high SHR levels were independently associated with in-hospital *** males with DM,hypertension,and decreased renal function had much higher risks of suffering from SHR-correlated MACEs.

关键词： acute cardiovascular finding

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease:baseline data and statistical analysis plan for the Lacunar Intervention trial-2(LACI-2)(ISRCTN14911850)

引用

Stroke & Vascular Neurology 2023年第2期8卷 134-143页

作者： philip M Bath Iris Mhlanga Lisa J Woodhouse Fergus Doubal Katherine Oatey Alan A Montgomery Joanna M Wardlaw LACI-trial investigators Stroke trials Unit University of NottinghamNottinghamUK Centre for Clinical Brain Sciences UK Dementia Research Institute CentreUniversity of EdinburghEdinburghUK Edinburgh Clinical trials Unit University of EdinburghEdinburghUK Nottingham Clinical trials Unit University of NottinghamNottinghamUK

Background Cerebral small vessel disease(SVD)causes lacunar strokes(25%of all ischaemic strokes),physical frailty and cognitive impairment and vascular and mixed *** is no specific treatment to prevent progression of *** The LACunar Intervention trial-2 is an investigator-initiated prospective randomised open-label blinded-endpoint phase II feasibility study assessing cilostazol and isosorbide mononitrate for preventing SVD *** aimed to recruit 400 patients with clinically evident lacunar ischaemic stroke and randomised to cilostazol,isosorbide mononitrate,both or neither,in addition to guideline secondary ischaemic stroke prevention,in a partial factorial *** primary outcome is feasibility of recruitment and adherence to medication;key secondary outcomes include:drug tolerability;recurrent vascular events,cognition and function at 1 year after randomisation;and safety(bleeding,falls,death).Data are number(%)and median(IQR).Results The trial commenced on 5 February 2018 and ceased recruitment on 31 May 2021 with 363 patients randomised,with the following baseline characteristics:average age 64(56.0,72.0)years,female 112(30.9%),stroke onset to randomisation 79.0(27.0,244.0)days,hypertension 267(73.6%),median blood pressures 143.0(130.0,157.0)/83.0(75.0,90.0)mm Hg,current smokers 67(18.5%),educationally achieved end of school examinations(A-level)or higher 118(32.5%),modified Rankin scale 1.0(0.0,1.0),National Institutes Health stroke scale 1.0(1.4),Montreal Cognitive Assessment 26.0(23.0,28.0)and total SVD score on brain imaging 1.0(0.0,2.0).This publication summarises the baseline data and presents the statistical analysis *** The trial is currently in follow-up which will complete on 31 May 2022 with results expected in October *** registration number ISRCTN14911850.

关键词： nitrate initiated prevention

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Diet and monensin influence the temporal dynamics of the rumen microbiome in stocker and finishing cattle

引用

Journal of Animal Science and Biotechnology 2024年第2期15卷 733-748页

作者： Jianmin Chai Caleb p.Weiss paul A.Beck Wei Zhao Ying Li Jiangchao Zhao Guangdong provincial Key Laboratory of Animal Molecular Design and precise Breeding College of Life Science and EngineeringFoshan UniversityFoshanChina Division of Agriculture Department of Animal ScienceUniversity of ArkansasFayettevilleARUSA Department of Animal and Food Sciences Oklahoma State UniversityStillwaterOKUSA Institute of Feed Research of Chinese Academy of Agricultural Sciences Key Laboratory of Feed Biotechnology of the Ministry of Agriculture and Rural AffairsBeijing 100193China

Background Stocker cattle diet and management influence beef cattle performance during the finishing stage,but knowledge of the dynamics of the rumen microbiome associated with the host are lacking.A longitudinal study was conducted to determine how the feeding strategy from the stocker to the finishing stages of production affects the temporal dynamics of rumen *** the stocker phase,either dry hay or wheat pasture were provided,and three levels of monensin were *** calves were then transported to a feedlot and received similar finishing diets with or without *** microbial samples were collected on d 0,28,85 during the stocker stage(S0,S28 and S85)and d 0,14,28,56,30 d before slaughter and the end of the trial during the finishing stage(F0,F14,F28,F56,pre-Ba,and Final).The V4 region of the bacterial 16S rRNA gene of 263 rumen samples was *** Higher alpha diversity,including the number of observed bacterial features and the Shannon index,was observed in the stocker phase compared to the finishing *** bacterial amplicon sequence variants(ASVs)differentiating different sampling time points were *** treatments during the stocker stage temporally impact the dynamics of rumen *** example,shared bacteria,including Bacteroidales(ASV19)and Streptococcus infantarius(ASV94),were significantly higher in hay rumen on S28,S85,and F0,while Bacteroidaceae(ASV11)and Limivicinus(ASV15)were more abundant in *** affected rumen microbial composition at a specific *** to feedlot significantly influenced microbiome structure and diversity in hay-fed *** taxa associated with body weight were classified,and core microbiotas interacted with each other during the *** In summary,the temporal dynamics of the rumen microbiome in cattle at the stocker and finishing stage are influenced by multiple factors of the feeding *** at the stocker phase may t

关键词： Beef cattle Diet Feedlot phase Monensin Next-generation sequencing Rumen microbiota Stocker

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Taking care of volunteers in a stroke trial: a new assisted-management strategy

引用

Stroke & Vascular Neurology 2016年第3期1卷 108-114页

作者： Amber C Stuart Jason J Sico Catherine M Viscoli Ashis H Tayal Silvio E Inzucchi Gary A Ford Karen L Furie Robert Cote J David Spence David Tanne Walter N Kernan on behalf of the IRIS trial investigators Department of Internal Medicine Yale University School of MedicineNew HavenConnecticutUSA Department of Neurology Yale University School of MedicineNew HavenConnecticutUSA Department of Neurology Service Veterans Affairs Connecticut Healthcare SystemWest HavenConnecticutUSA Neuroscience Institute Allegheny Health NetworkPittsburghPennsylvaniaUSA Lewis Katz School of Medicine at Temple University PhiladelphiaPennsylvaniaUSA Division of Medical Sciences Oxford UniversityOxfordUK The Warren Alpert Medical School of Brown University ProvidenceRhode IslandUSA Department of Neurology Neurosurgery and MedicineMcGill UniversityMontrealQuebecCanada University of Western Ontario LondonOntarioCanada 10Sheba Medical CenterTel Aviv UniversityTel AvivIsrael 不详

Background and purpose:providing participants with evidence-based care for secondary prevention is an ethical and scientific priority for trials in stroke *** optimal strategy,however,is *** report the performance of a new approach for delivering preventive care to trial ***:participants were enrolled in the Insulin Resistance Intervention after Stroke trial,which examined the insulin sensitiser,pioglitazone versus placebo for prevention of stroke and myocardial infarction after ischaemic stroke or transient ischaemic *** care was the responsibility of the participants’personal healthcare providers,but investigators monitored care and provided feedback *** studied achievement of 8 prevention goals at baseline and 3 annual visits,with a focus on 3 priority goals:blood pressurepoprotein(LDL)cholesterolproportion of participants achieving the priority goals was highest for antithrombotic use(96–99%in each year)and similar for blood pressure(66–72%in each year)and LDL(68–70%in each year).All 3 priority goals were achieved by 47–52%of participants in any given ***,only 22%of participants achieved all 3 goals in each ***:A strategy of monitoring care and providing feedback was associated with high average yearly achievement of 3 priority secondary prevention goals,but the majority of trial participants did not persist in being at goal over *** registration number:NCT00091949.

关键词： prevention annually goals

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Delivery room resuscitation intensity and associated neonatal outcomes of 24^(+0)-31^(+6) weeks'preterm infants in China:a retrospective cross-sectional study

引用

World Journal of pediatrics 2024年第1期20卷 64-72页

作者： Si-Lu Wang Chun Chen Xin-Yue Gu Zhao-Qing Yin Le Su Si-Yuan Jiang Yun Cao Li-Zhong Du Jian-Hua Sun Jiang-Qin Liu Chuan-Zhong Yang Department of Neonatology Shanghai Key Laboratory of Maternal Fetal MedicineShanghai Institute of Maternal-Fetal Medicine and Gynecologic OncologyShanghai First Maternity and Infant HospitalSchool of MedicineTongji UniversityNo.2699Gaoke Western RoadPudong DistrictShanghai 201204China Department of Neonatology Affiliated Shenzhen Maternity and Child Healthcare HospitalSouthern Medical UniversityNo.2004Hongli RoadFutian DistrictShenzhen 518028China NHC Key Laboratory of Neonatal Diseases Fudan UniversityChildren's Hospital of Fudan UniversityShanghaiChina Department of Neonatology People's Hospital of DehongKunming Medical UniversityDehongChina Department of Neonatology Children's Hospital of Fudan UniversityShanghaiChina Department of Neonatology Children's HospitalZhejiang University School of MedicineHangzhouChina Department of Neonatology Shanghai Children's Medical CenterSchool of MedicineShanghai Jiao Tong UniversityShanghaiChina

Background The aim of this study was to review current delivery room(DR)resuscitation intensity in Chinese tertiary neonatal intensive care units and to investigate the association between DR resuscitation intensity and short-term outcomes in preterm infants born at 24+0_31+6 weeks gestation age(GA).Methods This was a retrospective cross-sectional *** source population was infants born at 24+0_31+6 weeks'GA who were enrolled in the Chinese Neonatal Network 2019 *** infants were categorized into five groups:(1)regular care;(2)oxygen supplementation and/or continuous positive airway pressure(O2/CpAp);(3)mask ventilation;(4)endotracheal intubation;and(5)cardiopulmonary resuscitation(CpR).The association between DR resuscitation and shortterm outcomes was evaluated by inverse propensity score-weighted logistic *** Of 7939 infants included in this cohort,2419(30.5%)received regular care,1994(25.1%)received O,/CpAp,1436(18.1%)received mask ventilation,1769(22.3%)received endotracheal intubation,and 321(4.0%)received CpR in the *** maternal age and maternal hypertension correlated with a higher need for resuscitation,and antenatal steroid use tended to be associated with a lower need for resuscitation(ppairment increased significantly with increasing amounts of resuscitation in DR after adjusting for perinatal *** strategies vary widely between centers,with over 50%of preterm infants in eight centers requiring higher intensity *** Increased intensity of DR interventions was associated with increased mortality and morbidities in very preterm infants in *** is wide variation in resuscitative approaches across delivery centers,and ongoing quality improvement to standardize resuscitation practices is needed.

关键词： Cardiopulmonary resuscitation Delivery room Endotracheal intubation Neonatal resuscitation preterm

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial

引用

Stroke & Vascular Neurology 2016年第2期1卷 29-36页

作者： David Wang Li Gui Yi Dong Hao Li Shujuan Li Huaguang Zheng Anxin Wang Xia Meng Li-ping Liu Yi-Long Wang Guangyao Wang Jing Jing Zixiao Li Xing-Quan Zhao Yong-Jun Wang on behalf of the investigators for the CHANCE trial Illinois Neurological Institute Stroke Network Sisters of the Third Order of St.Francis Healthcare SystemUniversity of Illinois College of MedicinePeoriaIllinoisUSA Southwest Hospital Stroke Center Third Military University of Medical SciencesChongqingChina Department of Neurology Huashan HospitalFudan UniversityShanghaiChina China National Clinical Research Center for Neurological Diseases BeijingChina Chaoyang Hospital Neurology Department Capital Medical UniversityBeijingChina Department of Neurology Beijing Tiantan HospitalTiantan Clinical Trial and Research Center for StrokeCapital Medical UniversityBeijingChina Neurological Intensive Care Unit Beijing Tiantan HospitalCapital Medical UniversityBeijingChina Department of Neurology Beijing Tiantan HospitalVascular NeurologyCapital Medical UniversityBeijingChina 不详

Aim:The aim of this study was to explore the difference between haemorrhagic events among those patients on either aspirin or aspirin plus clopidogrel who were enrolled in the Clopidogrel in High-Risk patients with Acute Non-disabling Ischemic Cerebrovascular Events(CHANCE)***:This was an ad hoc analysis of the CHANCE trial;data on all patients with any haemorrhagic event were reviewed and *** proportional hazards regression was used to determine factors association with any ***:In the CHANCE trial,there were a total of 101(2%)haemorrhagic events reported from 50 different *** clopidogrel–aspirin group had 60(2.3%)cases and the aspirin group had 41(1.6%,p=0.09).Moderate or severe haemorrhagic events occurred in 7 patients(0.3%)in the clopidogrel–aspirin group and in 8(0.3%)in the aspirin group(p=0.73).Of 36(0.7%)cases of intracranial haemorrhages,20(0.4%)were in the clopidogrel–aspirin group and 16(0.3%)in the aspirin *** group had 8(0.3%)cases of symptomatic haemorrhagic *** common haemorrhagic events included 24(0.5%)cases of skin bruises,13(0.3%)gastrointestinal haemorrhages,9(0.2%)gum haemorrhages and 8(0.2%)intraocular ***:There was no overall significant difference in haemorrhagic events(p=0.29),especially in the rate of intracranial haemorrhages between the 2 treatment ***,patients enrolled with minor strokes had an increased risk of haemorrhagic events regardless of treatment group,not seen in patients with high-risk transient ischaemic *** elderly,of male gender and with a history of aspirin or proton pump inhibitor usage were associated with increased risk of *** with higher body mass index had lower risk of haemorrhagic events.

关键词： patients intracranial analysis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Oral anti-coagulants use in Chinese hospitalized patients with atrial fibrillation

引用

Chinese Medical Journal 2024年第2期137卷 172-180页

作者： Jing Lin Deyong Long Chenxi Jiang Caihua Sang Ribo Tang Songnan Li Wei Wang Xueyuan Guo Man Ning Zhaoqing Sun Na Yang Yongchen Hao Jun Liu Jing Liu Xin Du Louise Morgan Gregg C.Fonarow Sidney C.Smith Jr Gregory Y.H.Lip Dong Zhao Jianzeng Dong Changsheng Ma On behalf of CCC-AF investigators Department of Cardiology Beijing Anzhen HospitalCapital Medical UniversityBeijing 100029China National Clinical Research Center for Cardiovascular Diseases Beijing 100029 China Department of Epidemiology Beijing Anzhen HospitalCapital Medical UniversityBeijing Institute of HeartLung and Blood Vessel DiseasesBeijing 100029China International Quality Improvement Department American Heart AssociationDallasTX 07076USA Division of Cardiology Geffen School of Medicine at University of CaliforniaLos Angeles CA 90024USA Division of Cardiology University of North CarolinaChapel HillNC 27599USA Department of Cardiology Liverpool Centre for Cardiovascular ScienceUniversity of Liverpool and Liverpool Heart&Chest HospitalLiverpool L143PEUK Department of Clinical Medicine Aalborg UniversityAalborg 9000Denmark 不详

Background:Oral anti-coagulants(OAC)are the intervention for the prevention of stroke,which consistently improve clinical outcomes and survival among patients with atrial fibrillation(AF).The main purpose of this study is to identify problems in OAC utilization among hospitalized patients with AF in ***:Using data from the Improving Care for Cardiovascular Disease in China-Atrial Fibrillation(CCC-AF)registry,guideline-recommended OAC use in eligible patients was ***:A total of 52,530 patients with non-valvular AF were enrolled from February 2015 to December 2019,of whom 38,203 were at a high risk of stroke,9717 were at a moderate risk,and 4610 were at a low *** admission,only 20.0%(6075/30,420)of patients with a diagnosed AF and a high risk of stroke were taking *** use of pre-hospital OAC on admission was associated with a lower risk of new-onset ischemic stroke/transient ischemic attack among the diagnosed AF population(adjusted odds ratio:0.54,95%confidence interval:0.43-0.68;pprescription rate of OAC was 45.2%(16,757/37,087)in eligible patients with high stroke risk and 60.7%(2778/4578)in eligible patients with low stroke *** utilization in patients with high stroke risk on admission or at discharge both increased largely over time(all ppositively associated with in-hospital rhythm control strategies,including catheter ablation(adjusted odds ratio[OR]11.63,95%confidence interval[CI]10.04-13.47;ppppitals participated in the CCC-AF project,>70%of AF patients were at a high risk of *** poor performance on guideline-recommended OAC use was found in this study,over time the CCC-AF project has made progress in stroke prevention in the Chinese AF ***

关键词： Atrial fibrillation Oral anti-coagulants OAC Stroke prevention Contraindication

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Effect of complete revascularization in acute coronary syndrome after 75 years old:insights from the BleeMACS registry

引用

Journal of Geriatric Cardiology 2023年第10期20卷 728-736页

作者： Ge WANG Xiu-Huan CHEN Si-Yi LI Ze-Kun ZHANG Wei GONG Yan YAN Shao-ping NIE Josép.Henriques on behalf of the BleeMACS registry investigators Center for Coronary Artery Disease Beijing Anzhen HospitalCapital Medical UniversityBeijingChina Department of Cardiology Amsterdam University Medical CenterAmsterdamthe Netherlands 不详

BACKGROUND The prognostic benefit of complete revascularization in elderly patients(aged over 75 years)with multi-vessel disease and acute coronary syndrome(ACS)is currently *** study aimed to determine the long-term prognostic impact of complete revascularization in this *** We conducted this study using data obtained from the BleeMACS(Bleeding complications in a Multicenter registry of patients discharged after an Acute Coronary Syndrome)registry,which was carried out from 2003 to *** objective was to categorize older patients diagnosed with ACS into two groups:those who underwent complete revascularization and those who did *** score matching and the Kaplan-Meier analysis were employed to examine differences in one-year clinical *** primary endpoint was major adverse cardiovascular event(MACE),which encompassed a combination of all-cause mortality and myocardial *** Out of 1263 patients evaluated,445 patients(35.2%)received complete *** who underwent complete revascularization had a higher prevalence of hypertension and prior percutaneous coronary intervention compared to those who did *** the one-year follow-up period,complete revascularization was associated with a significantly decreased risk of MACE[13.7%vs.20.5%,hazard ratio(HR)=0.63,95%CI:0.45–0.88,p=0.007]and a lower risk of myocardial infarction(5.9%vs.9.9%,HR=0.55,95%CI:0.33–0.92,p=0.02).However,it was not linked to a lower risk of all-cause death(9.5%vs.13.5%,HR=0.68,95%CI:0.45–1.02,p=0.06).Similar results were observed in the subgroup *** Long-term clinical improvements were observed in ACS patients aged over 75 years with multi-vessel disease who achieved complete ***,adhering to guidelines for complete revascularization should be recommended for elderly patients.

关键词： coronary revascularization acute

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

培哚普利治疗稳定性冠心病的耐受性研究

引用

中华心血管病杂志 2007年第12期35卷 1130-1132页

作者： The investigators for the Study on the Tolerability of perindopril 培哚普利耐受性研究协作组

目的对稳定性冠心病患者,观察将培哚普利由4mg/d 调整至8mg/d 后的耐受性。方法开放性多中心研究。入组已经服用培哚普利4 mg/d 至少4周的稳定性冠心病患者,采用培哚普利8 mg/d 治疗2个月,观察增量后的安全性与耐受性。观察指标:不良事... 详细信息

目的对稳定性冠心病患者,观察将培哚普利由4mg/d 调整至8mg/d 后的耐受性。方法开放性多中心研究。入组已经服用培哚普利4 mg/d 至少4周的稳定性冠心病患者,采用培哚普利8 mg/d 治疗2个月,观察增量后的安全性与耐受性。观察指标:不良事件和严重不良事件、患者依从性,记录基线状态、第4周和第8周的血压、心率、血钾、钠、肌酐和尿素氮。结果共入选109例符合入选标准的稳定性冠心病患者。其中102例患者能够很好耐受培哚普利8 mg/d 治疗,总耐受率为93.6%。共计18例患者(占16.5%)发生不良事件,无严重不良事件发生。仅1例患者(占0.9%)因不良事件退出。培哚普利增量使基线血压未达标患者的血压由(149.4±7.6)/(84.1±11.0)mm Hg(1 mm Hg=0.133 kpa)下降至(128.8±14.2)/(79.5±8.9)mm Hg(均 pp<0.05),血电介质、肌酐和尿素氮水平无变化。结论中国稳定性冠心病患者对培哚普利8 mg/d 的治疗剂量耐受性良好。

关键词：冠状动脉疾病血管紧张素转换酶抑制药药物耐受性培哚普利稳定性冠心病

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：